CASE REPORT article
Front. Oncol.
Sec. Cardio-Oncology
This article is part of the Research TopicCase Reports in Cardio-Oncology: 2025View all 9 articles
Fatal Myocarditis and Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: Concurrent Dual Adverse Events in an Older Adult
Provisionally accepted
- American University of Beirut Medical Center, Beirut, Lebanon
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic renal cell carcinoma (RCC), offering significant survival benefits. Their use, however, can come at the expense of severe immune-related adverse events (irAEs) involving the myocardium and nervous system. We report an 86-year-old male with relapsed clear cell RCC (Fuhrman grade 3, pT3aN0M0) who developed concurrent myocarditis and myasthenia gravis (MG) after receiving Pembrolizumab and Axitinib for multifocal mediastinal relapse. Despite early initiation of high-dose IV methylprednisolone within 24 hours, the patient's condition deteriorated rapidly, resulting in pneumonia, acute kidney injury requiring hemodialysis, and death. This case highlights the fulminant course of ICI-induced myocarditis and MG, underscoring the importance of prompt recognition, immediate initiation of corticosteroids and IV immunoglobulin, and early consideration of second-line immunomodulatory therapies in severe cases.
Keywords: Immune checkpoint inhibitor, Myocarditis, Myasthenia Gravis, Renal cell carcinoma, Immunotherapy
Received: 07 May 2025; Accepted: 01 Dec 2025.
Copyright: © 2025 Fakhreddine, Assaad, El Meski, Kreidieh, Alam and Khoury. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Maurice Khoury
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.